

**THE AMENDMENT**

**In the Specification:**

Please amend the table starting at page 43, line 13:

Protein	Accession Number	Name	<u>SEQ ID NO</u>	Peptide	Theoretical Scores	
					Ken Parker	SYFPEITHI
TGF-betaRII (-1)	AAA61164	FSP01	<u>75</u>	<sup>128</sup> -SLVRLSSCV	70	23
TGF-betaRII (-1)	AAA61164	FSP02	<u>76</u>	<sup>131</sup> -RLSSCVPA	5	19
TGF-betaRII (-1)	AAA61164	FSP03	<u>77</u>	<sup>135</sup> -CVPVALMSA	1	14
HPDMPK (-1)	CAA71862	FSP04	<u>78</u>	<sup>136</sup> -LLHSAPTPSL	36	25
HPDMPK (-1)	CAA71862	FSP05	<u>79</u>	<sup>129</sup> -FLSASHFLL	570	21
HPDMPK (-1)	CAA71862	FSP07	<u>80</u>	<sup>125</sup> -RVFFFYQHL	39	15
OGT (-1)	AAB63466	FSP06	<u>81</u>	<sup>128</sup> -SLYKFSPFPL	397	23
D070 (-1)	BAA11534	FSP08	<u>82</u>	<sup>35</sup> -KIFTFFFQL	1593	21
D070 (-1)	BAA11534	FSP09	<u>83</u>	<sup>68</sup> -ALLPAGPLT	28	21
D070 (-1)	BAA11534	FSP10	<u>84</u>	<sup>69</sup> -LLPAGPLTQT	29	20
U79260 (-1)	AAB50206	FSP11	<u>85</u>	<sup>59</sup> -TLSPGWSAV	118	25
U79260 (-1)	AAB50206	FSP12	<u>86</u>	<sup>83</sup> -ILLPQPPEWL	362	26
Sec63 (-1)	AAC83375	FSP13	<u>87</u>	<sup>551</sup> -RQMESLGMKL	33	15
MAC30X (-1)	AAA16188	FSP14	<u>88</u>	<sup>198</sup> -VEMPTGWLL	20	14
MAC30X (-1)	AAA16188	FSP15	<u>89</u>	<sup>198</sup> -VEMPTGWLLV	14	15
FLT3L (-1)	U29874	FSP16	<u>90</u>	<sup>113</sup> -FQPPPAVFA	13	10
MSH-3 (-1)	AAB47281	FSP17	<u>91</u>	<sup>389</sup> -ALWECSLPQA	389	24
MSH-3 (-1)	AAB47281	FSP18	<u>92</u>	<sup>386</sup> -FLLALWECSL	364	25
MSH-3 (-1)	AAB47281	FSP19	<u>93</u>	<sup>387</sup> -LLALWECSL	36	26
MSH-3 (-1)	AAB47281	FSP20	<u>94</u>	<sup>394</sup> -SLPQARLCL	21	23
MSH-3 (-1)	AAB47281	FSP21	<u>95</u>	<sup>402</sup> -LIVSRTLLL	5	23
MSH-3 (-1)	AAB47281	FSP22	<u>96</u>	<sup>401</sup> -CLIVSRTLL	21	22
MSH-3 (-1)	AAB47281	FSP23	<u>97</u>	<sup>403</sup> -IVSRTLLLV	24	21
MSH-3 (-1)	AAB47281	FSP24	<u>98</u>	<sup>382</sup> -KRATFLLAL	0,1	20
Caspase-5 (-1)	U28015	FSP25	<u>99</u>	<sup>61</sup> -KMFFMVFLI	1301	20
Caspase-5 (-1)	U28015	FSP26	<u>100</u>	<sup>67</sup> -FLIWQNTM	22,85	21
TAF-1b (-1)	L39061	FSP27	<u>101</u>	<sup>108</sup> -GMCVKVSSI	17	24
HT001 (-1)	NP 054784	FSP30	<u>102</u>	<sup>281</sup> -VLRTEGEPL	n.d.	21

MSH-3 (-1)	AAB47281	FSP31	<u>103</u>	<sup>402</sup> LIVSRTLLL	37	25
MSH-3 (-1)	AAB47281	FSP32	<u>104</u>	<sup>394</sup> SLPQARLCLI	24	24
MSH-3 (-1)	AAB47281	FSP33	<u>105</u>	<sup>401</sup> CLIVSRTLLL	21	23
MSH-3 (-1)	AAB47281	FSP34	<u>106</u>	<sup>399</sup> RLCLIVSRTL	4	22

Please amend the paragraph starting at page 45, line 28:

For the test synthetic peptides representing immunogenic portions of all relevant frameshift peptides (see figure 5 2) arising from the respective genes were spotted onto nylon membranes. The nylon membranes were subsequently incubated for one hour in phosphate-buffered saline (PBS) with 5% milk powder for blocking unspecific membrane binding. After washing the membranes 3x with PBS, the membranes were incubated with the test and control sera. The sera were diluted 1:1.000 in PBS/0,5% milk powder and incubated overnight with gentle shaking. Subsequently the sera were removed, and membranes were washed three times in PBS before they were incubated with a polyclonal alkaline phosphatase conjugated goat anti-human IgG antibody for one hour. Thereafter, the membranes were washed repeatedly with PBS/0,05% TWEEN20 before staining reaction was developed using nitroblue tetrazolium chloride and bromochloro-indoyl-phosphate (SigmaAldrich) in Tris-buffered saline (TBS). Binding of human antibodies specific for individual frameshift polypeptides thus was made visible by color-deposit on the respective membrane.